{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T18:38:29Z","timestamp":1774723109797,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine what dose of melatonin is most effective for treating migraine acutely in children and adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute migraine medications may not work for all patients and may cause side effects. Melatonin is effective for migraine prevention in adults and has been used acutely for procedural pain in children. Our goal was to determine whether a \u201chigh\u201d or \u201clow\u201d dose of melatonin is more effective for treating migraine acutely in youth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this pilot, randomized, open\u2010label, single\u2010center, dose\u2010finding trial, children and adolescents aged 4\u201017\u00a0years with episodic migraine were randomized to \u201chigh\u2010dose\u201d or \u201clow\u2010dose\u201d dose melatonin (&lt;40\u00a0kg: 4\u00a0mg vs. 1\u00a0mg; \u226540\u00a0kg: 8\u00a0mg vs. 2\u00a0mg). The primary outcome measure was change in mean pain score between time 0 and 2\u00a0hours. Secondary outcomes included 2\u2010hour pain\u2010relief and pain\u2010freedom rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty\u2010four participants (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a042 per group) were enrolled in this study. Mean (SD) participant age was 11.8 (3.5) years and 55% (46\/84) were female. Mean (SD) headache days\/month was 5.6 (3.8). Sixty\u2010six (79%) participants provided outcome data and were included in the analyses,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a024 in the high\u2010dose group and\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a022 in the low\u2010dose group. The drop\u2010out rate was 43% (18\/42) in the high\u2010dose group vs. 48% (20\/42) in the low\u2010dose group. Mean (SD) change in pain intensity at 2 hours was \u22122.7 (2.1) cm in the high\u2010dose group vs. \u22122.3 (2.1) cm in the low\u2010dose group (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.581), a difference of 0.4\u00a0cm (95% CI: \u22121.17 to 1.92). Two\u2010hour pain\u2010freedom rate was 41% (7\/17) vs. 27% (4\/15) in the high\u2010dose vs. low\u2010dose groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.415), and 2\u2010hour pain\u2010relief rate was 94% (16\/17) vs. 80% (12\/15), (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.482). There were no serious adverse events. Napping occurred in the majority (67% (14\/21) high dose vs. 47% (9\/19) low dose). Higher mg\/kg dose of melatonin and napping were each independently associated with greater headache benefit.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>As an acute treatment for pediatric migraine,\u00a0both low and high doses of melatonin were associated with pain reduction; however, study drop\u2010out was high. Higher dose and napping after treatment predicted greater benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.13934","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T02:21:01Z","timestamp":1599099661000},"page":"1712-1721","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial"],"prefix":"10.1111","volume":"60","author":[{"given":"Amy A.","family":"Gelfand","sequence":"first","affiliation":[{"name":"Department of Neurology UCSF Child &amp; Adolescent Headache Program San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra C.","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Pediatrics UCSF Child &amp; Adolescent Headache Program San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6564-7986","authenticated-orcid":false,"given":"Samantha L.","family":"Irwin","sequence":"additional","affiliation":[{"name":"Department of Neurology UCSF Child &amp; Adolescent Headache Program San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlin A.","family":"Greene","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology Department of Pediatrics Oregon Health &amp; Science University Portland OR USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William F.","family":"Qubty","sequence":"additional","affiliation":[{"name":"Pediatric Headache Program Dell Medical School University of Texas at Austin Austin TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. Elaine","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology &amp; Biostatistics University of California San Francisco San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102409355601"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318271f812"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.1.e1"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13628"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13284"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.80.7_supplement.S40.005","article-title":"Double\u2010blind, placebo controlled, randomized clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention","volume":"80","author":"Peres M","year":"2013","journal-title":"Neurology"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0285"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574886309666140605114614"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12862"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00089.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2009.01.024"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3565"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-200112000-00021"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-079X.2011.00941.x"},{"key":"e_1_2_6_16_1","first-page":"509","article-title":"Potential use of melatonin in procedural anxiety and pain in children undergoing blood withdrawal","volume":"29","author":"Marseglia L","year":"2015","journal-title":"J Biol Regul Homeost Agents"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNR.0b013e3280101207"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01546.x"},{"key":"e_1_2_6_20_1","volume-title":"Wong\u2010Baker FACES\u00ae Pain Rating Scale","author":"Wong\u2010Baker FACES Foundation"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0775-3"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/acem.12620"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-6618(02)00094-4"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.76.2.295"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2009.12.001"},{"key":"e_1_2_6_26_1","first-page":"274","article-title":"Melatonin and its agonists in pain modulation and its clinical application","volume":"150","author":"Srinivasan V","year":"2012","journal-title":"Arch Ital Biol"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13898"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610384"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-018-3415-1"},{"key":"e_1_2_6_30_1","unstructured":"Candies milk chocolate.U.S. Department of Agriculture Food Data Central;2020. Available at:https:\/\/fdc.nal.usda.gov\/fdc\u2010app.html#\/food\u2010details\/167587\/nutrients."},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-981467"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/crad.2001.0923"}],"updated-by":[{"DOI":"10.1111\/head.14137","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000}}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13934","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.13934","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:27:27Z","timestamp":1762072047000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.13934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/head.13934"],"URL":"https:\/\/doi.org\/10.1111\/head.13934","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"2020-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}